Substrate reduction therapy
The glycosphingolipidoses are a family of storage diseases that arise due to incomplete catabolism of glycosphingolipids (GSLs) in the lysosome (Wraith, 2002). The majority are autosomal recessive disorders and result from mutations in the genes that encode the catabolic enzymes of the lysosome (Win...
Auteurs principaux: | Platt, F, Butters, T |
---|---|
Format: | Book section |
Publié: |
Springer US
2007
|
Documents similaires
-
Substrate reduction therapy in mouse models of the glycosphingolipidoses.
par: Platt, F, et autres
Publié: (2003) -
Substrate reduction therapy.
par: Platt, F, et autres
Publié: (2008) -
Substrate reduction therapy for glycosphingolipid storage disorders.
par: Lachmann, R, et autres
Publié: (2001) -
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
par: Andersson, U, et autres
Publié: (2004) -
Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
par: Platt, F, et autres
Publié: (2000)